Diversified healthcare company CVS Health (NYSE: CVS) will be reporting earnings this Wednesday before market open. Here’s what investors should know.
CVS Health beat analysts’ revenue expectations last quarter, reporting revenues of $105.7 billion, up 8.2% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts’ revenue estimates but a slight miss of analysts’ full-year EPS guidance estimates.
Is CVS Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting CVS Health’s revenue to be flat year on year, slowing from the 7% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CVS Health has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at CVS Health’s peers in the health insurance providers segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 7.1%, beating analysts’ expectations by 6.2%, and Elevance Health reported revenues up 1.5%, topping estimates by 2.4%. Centene traded up 24.1% following the results while Elevance Health was also up 5.5%.
Read our full analysis of Centene’s results here and Elevance Health’s results here.
There has been positive sentiment among investors in the health insurance providers segment, with share prices up 5.7% on average over the last month. CVS Health is up 12% during the same time and is heading into earnings with an average analyst price target of $96.58 (compared to the current share price of $82.06).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
